EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Dual Immune Checkpoints PD‐L1 and HLA‐G by Trispecific T Cell Engager for Treating Heterogeneous Lung Cancer

Yu-Chuan Lin iD, Mei-Chih Chen iD, Shi-Wei Huang iD, Yeh Chen iD, Jennifer Hui-Chun Ho, Fang-Yu Lin, Xiao-Tong Tan, Hung-Che Chiang, Chiu-Ching Huang iD, Chih-Yen Tu iD, Der-Yang Cho iD, Shao-Chih Chiu iD

Advanced Science · 2024

DOI: 10.1002/advs.202309697 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Yu-Chuan Lin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Translational Cell Therapy Center, China Medical University Hospital, No. 2, Yude Rd., North Dist., Taichung City, 404, Taiwan. Hauptthemen laut MEDLINE: Lung Neoplasms, B7-H1 Antigen, HLA-G Antigens, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology/National Science and Technology Council, CMUH Cancer Research Center of Excellence, China Medical University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy targeting immune checkpoints (ICPs), such as programmed death‐ligand‐1 (PD‐L1), is used as a treatment option for advanced or metastatic non‐small cell lung cancer (NSCLC). However, overall response rate to anti‐PD‐L1 treatment is limited due to antigen heterogeneity and the immune‐suppressive tumor microenvironment. Human leukocyte antigen‐G (HLA‐G), an ICP as well as a neoexpressed tumor‐associated antigen, is previously demonstrated to be a beneficial target in combination with anti‐PD‐L1. In this study, a nanobody‐based trispecific T cell engager (Nb‐TriTE) is developed, capable of simultaneously binding to T cells, macrophages, and cancer cells while redirecting T cells toward tumor cells expressing PD‐L1‐ and/or HLA‐G. Nb‐TriTE shows broad spectrum anti‐tumor effects in vitro by augmenting cytotoxicity mediated by human peripheral blood mononuclear cells (PBMCs). In a humanized immunodeficient murine NSCLC model, Nb‐TriTE exhibits superior anti‐cancer potency compared to monoclonal antibodies and bispecific T cell engagers. Nb‐TriTE, at the dose with pharmacoactivity, does not induce additional enhancement of circulating cytokines secretion from PMBCs. Nb‐TriTE effectively prolongs the survival of mice without obvious adverse events. In conclusion, this study introduces an innovative therapeutic approach to address the challenges of immunotherapy and the tumor microenvironment in NSCLC through utilizing the dual ICP‐targeting Nb‐TriTE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsB7-H1 AntigenHLA-G AntigensCarcinoma, Non-Small-Cell LungAnimalsHumansMiceT-LymphocytesImmunotherapyTumor MicroenvironmentDisease Models, AnimalCell Line, Tumor

Stichwörter der Autor:innen

human leukocyte antigen‐G (HLA‐G)immune checkpoint (ICP)nanobody‐based trispecific T cell engager (Nb‐TriTE)non‐small cell lung cancer (NSCLC)programmed death‐ligand 1 (PD‐L1)

Substanzen

B7-H1 AntigenHLA-G AntigensCD274 protein, human

Autor:innen und Institutionen

  • Translational Cell Therapy Center, China Medical University Hospital, No. 2, Yude Rd., North Dist., Taichung City, 404, Taiwan.
  • Shine-On BioMedical Co. Ltd., Rm. B, 10F., No. 573, Sec. 2, Taiwan Blvd., West Dist., Taichung City, 403, Taiwan.
  • Institute of New Drug Development, China Medical University, Taichung City, 404, Taiwan.
  • Institute of Biomedical Sciences, National Chung Hsing University, Taichung City, 402, Taiwan.
  • Department of Food Science and Biotechnology, National Chung Hsing University, Taichung City, 402, Taiwan.
  • Center for Translational Genomics and Regenerative Medicine Research, China Medical University Hospital, Taichung City, 404, Taiwan.

ORCID-Profile: Yu-Chuan Lin, Mei-Chih Chen, Shi-Wei Huang, Yeh Chen, Chiu-Ching Huang, Chih-Yen Tu, Der-Yang Cho, Shao-Chih Chiu

Förderung

  • Ministry of Science and Technology/National Science and Technology Council
  • CMUH Cancer Research Center of Excellence
  • China Medical University Hospital

Zitieren

APA

Lin, Y. C., Chen, M. C., Huang, S. W., Chen, Y., Ho, J. H., Lin, F. Y., Tan, X. T., Chiang, H. C., Huang, C. C., Tu, C. Y., Cho, D. Y., & Chiu, S. C. (2024). Targeting Dual Immune Checkpoints PD‐L1 and HLA‐G by Trispecific T Cell Engager for Treating Heterogeneous Lung Cancer. Advanced Science. https://doi.org/10.1002/advs.202309697

Vancouver

Lin YC, Chen MC, Huang SW, Chen Y, Ho JH, Lin FY, et al. Targeting Dual Immune Checkpoints PD‐L1 and HLA‐G by Trispecific T Cell Engager for Treating Heterogeneous Lung Cancer. Advanced Science. 2024. doi:10.1002/advs.202309697

BibTeX
@article{Lin2024,
  author = {Lin, Yu-Chuan and Chen, Mei-Chih and Huang, Shi-Wei and Chen, Yeh and Ho, Jennifer Hui-Chun and Lin, Fang-Yu and Tan, Xiao-Tong and Chiang, Hung-Che and Huang, Chiu-Ching and Tu, Chih-Yen and Cho, Der-Yang and Chiu, Shao-Chih},
  title = {Targeting Dual Immune Checkpoints PD‐L1 and HLA‐G by Trispecific T Cell Engager for Treating Heterogeneous Lung Cancer},
  journal = {Advanced Science},
  year = {2024},
  doi = {10.1002/advs.202309697}
}
Kostenlos starten →